$ASTH

Astrana Health (ASTH), a healthcare management company, reported Q2 revenue growth of 49% YoY and expects 25% growth in FY2026. The company has a market cap of $1.9B, trades at $38/share, and aims to reduce its leverage ratio. Analysts project EPS to triple this year and continue growing. The author suggests a covered call strategy for investing in ASTH.

Alignment Healthcare (ALHC) will add Astrana Health to its Medicare Advantage network in seven California counties from January 2027, expanding access to 3,000 PCPs and 6,500 specialists. This move supports ALHC's growth strategy in key markets.

Verda Healthcare, a Medicare Advantage plan, partners with AstranaCare Partners to serve Pan-Asian, Hispanic, and Arab American communities in Texas and Arizona. Astrana Health (NASDAQ: ASTH) brings expertise in value-based care. Verda aims to improve healthcare for underrepresented groups.

Astrana Health (ASTH) stock has risen 35.1% in six months, reaching $37.03. The company, formerly Apollo Medical Holdings, reported 40.2% revenue growth and 11.6% EPS growth over five years. However, its return on invested capital has declined. The stock trades at 11.1× forward P/E. Analysts debate its valuation and potential for new investments.

Alignment Healthcare (ALHC) announced its Medicare Advantage plan will expand to three new California counties in 2027, adding Hoag and Astrana Health to its provider network, totaling 25 counties served.

Astrana Health notified the SEC of a data breach caused by a social engineering attack, potentially exposing patient, provider, and corporate data. The company is investigating and has taken remedial actions. Astrana, with 2025 revenue of $3.2B, stated the incident is material but does not expect it to affect its financial condition or operations. The company has cyber insurance but cannot guarantee it will cover all losses.

Astrana Health (ASTH) shares fell 5.5% after disclosing a cybersecurity incident and data breach at its subsidiary, adding to existing pressures from a securities-law investigation and Medicare regulatory concerns. The stock is volatile, down 33.3% from its 52-week high, and up 31.7% year-to-date. Investors are assessing the long-term impact of potential Medicare Advantage reforms on the company's margins.

Astrana Health ASTH fell 7% premarket after reporting a 'material' cybersecurity incident at its subsidiary, Astrana Health Management. The breach involved unauthorized access to private/confidential data via social engineering. The company is investigating and stated the incident won't materially impact its financials, as of Sept. 22.

Astrana Health (ASTH) shares dropped 6% after Glass House Research criticized its accounting, questioning profit sustainability and organic growth. The report highlighted concerns over acquisition-related marks, related-party loans, and Medicare exposure. ASTH's 2025 revenue fell 3.5%, and net income was $1.2 million. The firm also noted rising claims expenses and negative capital allocation.

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.